125 related articles for article (PubMed ID: 35285092)
1. Impact of body size on skin-related adverse events in advanced prostate cancer treated with apalutamide: A multicenter retrospective study.
Sasaki D; Hatakeyama S; Tanaka T; Okamoto T; Yoneyama T; Ohyama C
Int J Urol; 2022 Jul; 29(7):772-773. PubMed ID: 35285092
[No Abstract] [Full Text] [Related]
2. Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study.
Uemura H; Koroki Y; Iwaki Y; Imanaka K; Kambara T; Lopez-Gitlitz A; Smith A; Uemura H
BMC Urol; 2020 Sep; 20(1):139. PubMed ID: 32878613
[TBL] [Abstract][Full Text] [Related]
3. Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States.
Hussain A; Jiang S; Varghese D; Appukkuttan S; Kebede N; Gnanasakthy K; Macahilig C; Waldeck R; Corman S
BMC Cancer; 2022 Mar; 22(1):304. PubMed ID: 35317768
[TBL] [Abstract][Full Text] [Related]
4. Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.
Halabi S; Jiang S; Terasawa E; Garcia-Horton V; Ayyagari R; Waldeck AR; Shore N
J Urol; 2021 Aug; 206(2):298-307. PubMed ID: 33818140
[TBL] [Abstract][Full Text] [Related]
5. Low Body Weight as a Risk Factor for Apalutamide-related Cutaneous Adverse Events.
Katsuta M; Kimura T; Tashiro K; Murakami M; Hata K; Yanagisawa T; Onuma H; Yamamoto T; Sugaya S; Watanabe Y; Nobeyama Y; Egawa S; Asahina A
Anticancer Res; 2022 Apr; 42(4):2023-2028. PubMed ID: 35347024
[TBL] [Abstract][Full Text] [Related]
6. Real-world analysis of apalutamide-associated skin adverse events in Japanese patients with advanced prostate cancer: a multi-institutional study in the Chu-shikoku Japan Urological Consortium.
Tohi Y; Kato T; Fukuhara H; Kobayashi K; Ohira S; Ikeda K; Daizumoto K; Katayama S; Shimizu R; Nishimura K; Nagami T; Hayashida Y; Hirama H; Takamoto A; Dainichi T; Sugimoto M;
Int J Clin Oncol; 2022 Aug; 27(8):1348-1355. PubMed ID: 35596089
[TBL] [Abstract][Full Text] [Related]
7. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
Smith MR; Saad F; Chowdhury S; Oudard S; Hadaschik BA; Graff JN; Olmos D; Mainwaring PN; Lee JY; Uemura H; Lopez-Gitlitz A; Trudel GC; Espina BM; Shu Y; Park YC; Rackoff WR; Yu MK; Small EJ;
N Engl J Med; 2018 Apr; 378(15):1408-1418. PubMed ID: 29420164
[TBL] [Abstract][Full Text] [Related]
8. An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer.
Tsuchiya T; Imanaka K; Iwaki Y; Oyama R; Hashine K; Yamaguchi A; Uemura H
Int J Clin Oncol; 2019 Dec; 24(12):1596-1604. PubMed ID: 31446511
[TBL] [Abstract][Full Text] [Related]
9. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial.
Saad F; Cella D; Basch E; Hadaschik BA; Mainwaring PN; Oudard S; Graff JN; McQuarrie K; Li S; Hudgens S; Lawson J; Lopez-Gitlitz A; Yu MK; Smith MR; Small EJ
Lancet Oncol; 2018 Oct; 19(10):1404-1416. PubMed ID: 30213449
[TBL] [Abstract][Full Text] [Related]
10. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study.
Agarwal N; McQuarrie K; Bjartell A; Chowdhury S; Pereira de Santana Gomes AJ; Chung BH; Özgüroğlu M; Juárez Soto Á; Merseburger AS; Uemura H; Ye D; Given R; Cella D; Basch E; Miladinovic B; Dearden L; Deprince K; Naini V; Lopez-Gitlitz A; Chi KN;
Lancet Oncol; 2019 Nov; 20(11):1518-1530. PubMed ID: 31578173
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety Exposure-Response Relationships of Apalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer.
Perez-Ruixo C; Ackaert O; Ouellet D; Chien C; Uemura H; Olmos D; Mainwaring P; Lee JY; Yu MK; Perez-Ruixo JJ; Smith MR; Small EJ
Clin Cancer Res; 2020 Sep; 26(17):4460-4467. PubMed ID: 32561663
[TBL] [Abstract][Full Text] [Related]
12. Apalutamide: the established and emerging roles in the treatment of advanced prostate cancer.
Dellis AE; Papatsoris AG
Expert Opin Investig Drugs; 2018 Jun; 27(6):553-559. PubMed ID: 29856649
[TBL] [Abstract][Full Text] [Related]
13. Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study.
Chi KN; Chowdhury S; Bjartell A; Chung BH; Pereira de Santana Gomes AJ; Given R; Juárez A; Merseburger AS; Özgüroğlu M; Uemura H; Ye D; Brookman-May S; Mundle SD; McCarthy SA; Larsen JS; Sun W; Bevans KB; Zhang K; Bandyopadhyay N; Agarwal N
J Clin Oncol; 2021 Jul; 39(20):2294-2303. PubMed ID: 33914595
[TBL] [Abstract][Full Text] [Related]
14. ARNEO: neoadjuvant degarelix + apalutamide before surgery for high-risk prostate cancer.
Fenner A
Nat Rev Urol; 2022 Nov; 19(11):634. PubMed ID: 36195722
[No Abstract] [Full Text] [Related]
15. Apalutamide for the treatment of metastatic castration-sensitive prostate cancer.
Dror CM; Chi KN
Future Oncol; 2020 Dec; 16(35):2905-2916. PubMed ID: 32885994
[TBL] [Abstract][Full Text] [Related]
16. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
Chi KN; Agarwal N; Bjartell A; Chung BH; Pereira de Santana Gomes AJ; Given R; Juárez Soto Á; Merseburger AS; Özgüroğlu M; Uemura H; Ye D; Deprince K; Naini V; Li J; Cheng S; Yu MK; Zhang K; Larsen JS; McCarthy S; Chowdhury S;
N Engl J Med; 2019 Jul; 381(1):13-24. PubMed ID: 31150574
[TBL] [Abstract][Full Text] [Related]
17. Apalutamide-induced severe interstitial lung disease: A report of two cases from Japan.
Kobe H; Tachikawa R; Masuno Y; Matsunashi A; Murata S; Hagimoto H; Tomii K
Respir Investig; 2021 Sep; 59(5):700-705. PubMed ID: 34144936
[TBL] [Abstract][Full Text] [Related]
18. Apalutamide (Erleada) for prostate cancer.
Med Lett Drugs Ther; 2018 Jul; 60(1551):e124-e125. PubMed ID: 30036351
[No Abstract] [Full Text] [Related]
19. Matching-Adjusted Indirect Comparison of Health-Related Quality of Life and Adverse Events of Apalutamide Versus Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer.
Chowdhury S; Oudard S; Uemura H; Joniau S; Pilon D; Lefebvre P; McQuarrie K; Liu J; Dearden L; Sermon J; Van Sanden S; Diels J; Hadaschik BA
Adv Ther; 2020 Jan; 37(1):512-526. PubMed ID: 31813087
[TBL] [Abstract][Full Text] [Related]
20. Apalutamide: A Review in Metastatic Castration-Sensitive Prostate Cancer.
Hoy SM
Drugs; 2020 Oct; 80(15):1579-1585. PubMed ID: 32930958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
